Evidence map›Paper›PMID 34503178›Full record

ArticleCancers2021

Enhancement of Neuroblastoma NK-Cell-Mediated Lysis through NF-kB p65 Subunit-Induced Expression of FAS and PVR, the Loss of Which Is Associated with Poor Patient Outcome.

Elisa Brandetti, Chiara Focaccetti, Annalisa Pezzolo, Marzia Ognibene, Valentina Folgiero, Nicola Cotugno, Monica Benvenuto, Paolo Palma, Vittorio Manzari, Paolo Rossi and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. CD155 and Its Receptors as Targets for Cancer Therapy.International journal of molecular sciences · 2023
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Elisa BrandettiAcademic Department of Pediatrics (DPUO), Ospedale Pediatrico Bambino Gesù, IRCCS, 00165 Rome, Italy.
Chiara FocaccettiDepartment of Human Science and Promotion of the Quality of Life, San Raffaele Roma Open University, 00166 Rome, Italy.ORCID 0000-0002-7334-3966
Annalisa PezzoloIRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.
Marzia OgnibeneU.O.C. Genetica Medica, IRCCS Giannina Gaslini, 16147 Genoa, Italy.ORCID 0000-0003-3698-9319
Valentina FolgieroDepartment of Paediatric Haematology/Oncology and of Cell and Gene Therapy, Ospedale Pediatrico Bambino Gesù, IRCCS, 00165 Rome, Italy.
Nicola CotugnoResearch Unit of Clinical Immunology and Vaccinology, DPUO, Ospedale Pediatrico Bambino Gesù, IRCCS, 00165 Rome, Italy.
Monica BenvenutoDepartment of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0002-2520-1306
Paolo PalmaResearch Unit of Clinical Immunology and Vaccinology, DPUO, Ospedale Pediatrico Bambino Gesù, IRCCS, 00165 Rome, Italy.ORCID 0000-0002-3066-4719
Vittorio ManzariDepartment of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.
Paolo RossiAcademic Department of Pediatrics (DPUO), Ospedale Pediatrico Bambino Gesù, IRCCS, 00165 Rome, Italy.
Doriana FruciDepartment of Paediatric Haematology/Oncology and of Cell and Gene Therapy, Ospedale Pediatrico Bambino Gesù, IRCCS, 00165 Rome, Italy.ORCID 0000-0003-3388-7296
Roberto BeiDepartment of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0001-9541-8896
Loredana CifaldiAcademic Department of Pediatrics (DPUO), Ospedale Pediatrico Bambino Gesù, IRCCS, 00165 Rome, Italy.ORCID 0000-0001-5014-430X
Bambino Gesù Children's Hospital · ITUniversity of Rome Tor Vergata · ITIstituto Giannina Gaslini · IT

Funding

Italian Ministry of Health (Rome, Italy) GR-2011-02352151
6 · The paper itself

Abstract

High-risk neuroblastoma (NB) is a rare childhood cancer whose aggressiveness is due to a variety of chromosomal genetic aberrations, including those conferring immune evasion. Indeed, NB cells adopt several molecular strategies to evade recognition by the immune system, including the downregulation of ligands for NK-cell-activating receptors. To date, while molecular strategies aimed at enhancing the expression of ligands for NKG2D- and DNAM-1-activating receptors have been explored, no evidence has been reported on the immunomodulatory mechanisms acting on the expression of death receptors such as Fas in NB cells. Here, we demonstrated that transient overexpression of the NF-kB p65 subunit upregulates the surface expression of Fas and PVR, the ligand of DNAM-1, thus making NB cell lines significantly more susceptible to NK-cell-mediated apoptosis, recognition, and killing. In contrast, IFNγ and TNFα treatment, although it induced the upregulation of FAS in NB cells and consequently enhanced NK-cell-mediated apoptosis, triggered immune evasion processes, including the strong upregulation of MHC class I and IDO1, both of which are involved in mechanisms leading to the impairment of a proper NK-cell-mediated killing of NB. In addition, high-resolution array CGH analysis performed in our cohort of NB patients revealed that the loss of

Indexed as

FasneuroblastomaNK cell-mediated immunotherapyPVR

Identifiers

PMID34503178
PMCPMC8430542
OpenAlexW3197645592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.